Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04184973 · ClinicalTrials.gov registry record · NA

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

A NA study of Rectal Cancer and Rectal/Anal, sponsored by Colospan.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
14
Study locations

NCT04184973: Recruiting NA study of Rectal Cancer and Rectal/Anal, sponsored by Colospan.

NCT04184973 is a NA study of Rectal Cancer and Rectal/Anal that is actively recruiting participants, run by Colospan. The registered enrollment target is 250 participants, below the 3,163-participant average among 70 other Rectal Cancer trials with a reported enrollment target (92% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04184973, a NA study of Rectal Cancer and Rectal/Anal, is actively recruiting participants, sponsored by Colospan.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
14
Study locations

Study Summary

A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.

Interventions

  • DEVICE CG-100 intraluminal bypass device
  • PROCEDURE Stoma

Study Locations (14)

Other

  • Soroka University Medical Center - Beersheba
  • Carmel Medical Center - Haifa
  • Rabin Medical Center - Petah Tikva

California

  • University of California Irvine - Orange
  • Kaiser Permanente San Diego medical Center - San Diego

Colorado

  • Colorado University Anschutz Medical Campus - Aurora

Kentucky

  • University of Louisville - Louisville

Michigan

  • Henry Ford Health System - Detroit

Minnesota

  • East Bank Hospital - M Health Fairview University of Minnesota Medical Center - Minneapolis

New York

  • New York-Presbyterian / Weill Cornell Medical Center - New York

Pennsylvania

  • Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2020-06-23
Est. Completion 2026-12-31
Phase NA
Colospan

1 total trials

What NCT04184973 shows while recruiting

NCT04184973 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 3,163-participant average among 70 other Rectal Cancer trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Rectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which CG-100 intraluminal bypass device is the first listed.

NCT04184973 lists 14 locations in 11 states (Other, California, Colorado).

Frequently Asked Questions

What is clinical trial NCT04184973 about?

NCT04184973 is a clinical study titled "Efficacy and Safety of the CG-100 Intraluminal Bypass Device". A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.

What is the current status of trial NCT04184973?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2020-06-23. Estimated completion is 2026-12-31.

What conditions does trial NCT04184973 study?

This clinical trial studies the following conditions: Rectal Cancer, Rectal/Anal, Rectal Tumor.

What interventions are being tested in trial NCT04184973?

The interventions under investigation include: CG-100 intraluminal bypass device (DEVICE), Stoma (PROCEDURE).

Who is sponsoring clinical trial NCT04184973?

This trial is sponsored by Colospan, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04184973 being conducted?

This trial has 14 study locations across California, Colorado, Kentucky, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04184973's enrollment target sits among peer trials

250 14th of 70 higher than 56 of 70 other Rectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT04184973, the US trial registry maintained by the National Library of Medicine. NCT04184973 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.